Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
sal Polyps (sal Polyposis) - Overview
sal Polyps (sal Polyposis) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
sal Polyps (sal Polyposis) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
sal Polyps (sal Polyposis) - Companies Involved in Therapeutics Development
AptysBio Inc
F. Hoffmann-La Roche Ltd
GlaxoSmithKline Plc
Idorsia Pharmaceutical Ltd
Kyowa Kirin Co Ltd
Novartis AG
OptiNose US Inc
Pfizer Inc
Regeneron Pharmaceuticals Inc
Suzhou Connect Biopharmaceuticals Ltd
sal Polyps (sal Polyposis) - Drug Profiles
ACT-774312 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
benralizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CBP-201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dupilumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
etokimab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fevipiprant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fluticasone propiote - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
mepolizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
omalizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PF-06817024 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sal Polyps (sal Polyposis) - Dormant Projects
sal Polyps (sal Polyposis) - Discontinued Products
sal Polyps (sal Polyposis) - Product Development Milestones
Featured News & Press Releases
Oct 30, 2019: EC approves Dupixent’s indication in chronic rhinosinusitis
Sep 20, 2019: Sanofi : CHMP recommends approval of Dupixent (dupilumab) for severe chronic rhinosinusitis with sal polyposis
Sep 20, 2019: The Lancet publishes results from two positive phase 3 trials of Dupixent (dupilumab) in severe chronic Rhinosinusitis with sal Polyps
Sep 12, 2019: Optinose announces $150 million debt fincing from Pharmakon
Jun 27, 2019: FDA approves Regeneron’s antibody Dupixent for sal polyposis
Jun 26, 2019: FDA approves first treatment for chronic rhinosinusitis with sal polyps
Jun 03, 2019: Xolair (Omalizumab) significantly reduced sal polyps and congestion symptoms in adults with chronic rhinosinusitis with sal polyps in two phase III studies
May 07, 2019: Dupixent Filed for Sinusitis in Japan: Sanofi
Mar 11, 2019: FDA grants priority review for Sanofi’s Dupixent to treat rhinosinusitis
Feb 19, 2019: Optinose announces issuance of four additiol U.S. patents covering XHANCE
Feb 15, 2019: Optinose to highlight data at the 2019 AAAAI Annual Meeting in San Francisco
Dec 10, 2018: Optinose announces first patient enrolled in clinical trial of XHANCE for Chronic Sinusitis
Oct 18, 2018: Sanofi’s Dupixent meets Phase III trial endpoints for rhinosinusitis
Oct 03, 2018: Optinose to highlight data at two upcoming scientific meetings
Aug 30, 2018: European Commission approves Nucala (mepolizumab) for the treatment of children with severe asthma
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Figure 1: Number of Products under Development for Nasal Polyps (Nasal Polyposis), H2 2019
Figure 2: Number of Products under Development by Companies, H2 2019
Figure 3: Number of Products by Targets, H2 2019
Figure 4: Number of Products by Stage and Targets, H2 2019
Figure 5: Number of Products by Mechanism of Actions, H2 2019
Figure 6: Number of Products by Stage and Mechanism of Actions, H2 2019
Figure 7: Number of Products by Routes of Administration, H2 2019
Figure 8: Number of Products by Stage and Routes of Administration, H2 2019
Figure 9: Number of Products by Molecule Types, H2 2019
Figure 10: Number of Products by Stage and Molecule Types, H2 2019


List of Tables


Table 1: Number of Products under Development for Nasal Polyps (Nasal Polyposis), H2 2019
Table 2: Number of Products under Development by Companies, H2 2019
Table 3: Products under Development by Companies, H2 2019
Table 4: Number of Products by Stage and Target, H2 2019
Table 5: Number of Products by Stage and Mechanism of Action, H2 2019
Table 6: Number of Products by Stage and Route of Administration, H2 2019
Table 7: Number of Products by Stage and Molecule Type, H2 2019
Table 8: Nasal Polyps (Nasal Polyposis) - Pipeline by AnaptysBio Inc, H2 2019
Table 9: Nasal Polyps (Nasal Polyposis) - Pipeline by F. Hoffmann-La Roche Ltd, H2 2019
Table 10: Nasal Polyps (Nasal Polyposis) - Pipeline by GlaxoSmithKline Plc, H2 2019
Table 11: Nasal Polyps (Nasal Polyposis) - Pipeline by Idorsia Pharmaceutical Ltd, H2 2019
Table 12: Nasal Polyps (Nasal Polyposis) - Pipeline by Kyowa Kirin Co Ltd, H2 2019
Table 13: Nasal Polyps (Nasal Polyposis) - Pipeline by Novartis AG, H2 2019
Table 14: Nasal Polyps (Nasal Polyposis) - Pipeline by OptiNose US Inc, H2 2019
Table 15: Nasal Polyps (Nasal Polyposis) - Pipeline by Pfizer Inc, H2 2019
Table 16: Nasal Polyps (Nasal Polyposis) - Pipeline by Regeneron Pharmaceuticals Inc, H2 2019
Table 17: Nasal Polyps (Nasal Polyposis) - Pipeline by Suzhou Connect Biopharmaceuticals Ltd, H2 2019
Table 18: Nasal Polyps (Nasal Polyposis) - Dormant Projects, H2 2019
Table 19: Nasal Polyps (Nasal Polyposis) - Discontinued Products, H2 2019